Menu
Not yet recruiting NCT06247774

Reducing Heart Failure Risk in Late-Life With Physical Activity

No phase Interventional Hypertension Exercise Training Cardiac Rehabilitation Proteomics

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Cardiac Rehabilitation, Attention Control.
Who it may be relevant to
Registry conditions: Hypertension, Exercise Training, Cardiac Rehabilitation, Proteomics. Basic parameters: from 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Reducing Heart Failure Risk in Late-Life With Physical Activity: Impact on Cardiac Structure and Function and Proteomic Signatures

Overview

The goal of this clinical trial is to learn about the molecular pathways associated with the benefit of a regular exercise program in patients with high blood pressure and who don't already participate in regular exercise. The main question it aims to answer is to identify protein signatures associated with the benefits of a cardiac rehabilitation exercise program. The trial will enroll 42 participants, who will be randomized to a 12 week cardiac rehabilitation exercise program versus control arm and asked to participate in the following at the beginning and end of study: * Cardiopulmonary exercise test (CPET) * Echocardiogram * Physical function test * 6-minute walk test * Hand grip strength * Quality of life questionnaire * Blood draws Researchers will compare results between those who do and don't participate in the exercise program.

Detailed description

Lifestyle modification with physical activity (PA) appears to be protective of several age-related cardiovascular (CV) outcomes, including heart failure (HF), in a dose-dependent manner. While many studies with exercise training have demonstrated improvement in quality of life and cardiorespiratory fitness, findings have not been consistent with regards to the potential for exercise to preserve or even improve cardiac function in adults with HF. There remains incomplete understanding of the molecular pathways by which PA mitigates HF risk. Furthermore, exercise studies often exclude older adults, who are disproportionately affected by HF, though our preliminary data suggest the protective effects of PA extend to late-life. Older adults are at particularly heightened risk for HF with preserved ejection fraction (HFpEF), which is characterized by impaired left ventricular (LV) diastolic function and impaired systolic deformation despite preserved LV ejection fraction (LVEF). Unlike with HF with reduced ejection fraction (HFrEF), effective pharmacologic therapies or interventions to improve cardiac function among individuals with preserved LVEF are limited. Thus, there is a critical need to define the cardiovascular mechanisms by which PA impacts HF risk in older adults that may enable the identification of novel therapeutic targets to prevent HF and HFpEF in particular.

As proteins orchestrate and carry out cellular functions in health and in diseases, one method of characterizing changes in CV function is to investigate cell signaling by studying the circulating proteome. Proteomic approaches have previously been used to identify pathways relevant to myocardial infarction and have also been used to investigate molecular pathways characterizing PA and CV disease. A recent study demonstrated upregulation of inflammation-related proteins in HFpEF patients (n=228) compared to controls, and their association with worse indices of cardiac function. Specific proteomic patterns have also been associated with aerobic exercise, with 2 proteomic modules that were specifically preserved with aging in habitual exercisers. Data from Swedish cohorts has also shown an association of leisure-time PA with 28 CV-specific proteins involved in atherosclerotic processes. Serial multi-omic measures (including proteomics) have been used to demonstrate marked intra-individual changes in circulating proteins with acute exercise. More recently, high-throughput proteomic profiling has been successfully employed in younger adults to identify baseline protein levels associated with change in cardiorespiratory fitness following an exercise intervention. However, to-date, limited data exist regarding intervention-related changes in the proteome in older adults at risk for HF and the extent to which these changes correlate with changes in cardiorespiratory fitness.

Supervised exercise-training with cardiac rehabilitation (CR) has been well established as an effective method to improve maximal oxygen consumption (VO2 max), a measure of cardiorespiratory fitness. Improvement in VO2 max has also been demonstrated with exercise training in sedentary older adults over 65 years of age.

The objective of this proposal is to identify protein signatures characterizing the known benefits of a structured CR program on VO2 max. Our working hypotheses is that proteomic approaches will identify novel biomarkers that uniquely characterize molecular pathways associated with exercise training and CR-related changes in proteins will correlate with changes in VO2 max. Successful completion of this aim will identify possible novel protein signatures underlying the protective biological pathways mediated by a structured CR program that may be used as preliminary data for future grant proposals.

Aim: Identify molecular pathways underlying the beneficial effect of a structured PA intervention on functional capacity with the use of plasma proteomics in older sedentary adults at high risk of HF. (BWH-based cohort). Hypotheses: (1) Randomization to participation in a cardiac rehabilitation (CR) program will result in improvement in circulating levels of 4 plasma proteins associated with change in VO2max, a measure of cardiorespiratory fitness, and with genetic evidence supporting a causal effect on HF and cardiac structure (ATF6, STC1, JAG1, PTK7). The investigators will randomize 42 sedentary adults at high risk of HF (stage B HF) to participation in a CR program and perform proteomic analysis, cardiopulmonary exercise testing, and echocardiography at baseline and 12 weeks.

Interventions

  • Behavioral Cardiac Rehabilitation
    Participation in a 12-week cardiac rehabilitation program
  • Behavioral Attention Control
    Participants will receive regular phone calls in place of cardiac rehabilitation visits

Primary outcome measures

  • Impact of Cardiac Rehabilitation training on single protein changes [Time frame: 12 weeks]
Secondary outcome measures (12)
  • Correlation of change in proteins with change in VO2 max [Time frame: 12 weeks]
  • Correlation of change in proteins with change in LV global longitudinal strain [Time frame: 12 weeks]
  • Correlation of change in proteins with change in LV diastolic function [Time frame: 12 weeks]
  • Correlation of change in proteins with change in VE/VCO2 [Time frame: 12 weeks]
  • Correlation of change in proteins with change in Short Physical Performance Battery (SPPB) [Time frame: 12 weeks]
  • Correlation of change in proteins with change in 6-minute walk test [Time frame: 12 weeks]
  • Correlation of change in proteins with change in grip strength [Time frame: 12 weeks]
  • Correlation of change in proteins with change in EQ-5D (QOL) [Time frame: 12 weeks]
  • Correlation of change in proteins with change in step counts [Time frame: 12 weeks]
  • Correlation of baseline proteins with change in VO2 max [Time frame: 12 weeks]
  • Correlation of baseline proteins with change in LV global longitudinal strain [Time frame: 12 weeks]
  • Correlation of baseline proteins with change in LV diastolic function [Time frame: 12 weeks]

Eligibility criteria

Inclusion criteria

  • Hypertension (controlled on stable medication regimen)
  • Structural heart abnormality (LVH or LA enlargement)
  • LVEF > 50%
  • Sedentary
  • BMI <30

Exclusion criteria

  • Diabetes
  • Unable to exercise
  • Supplemental oxygen use
  • Pulmonary hypertension
  • Sleep apnea
  • Regular exercise training
  • Devices that limit ability to achieve target heart rate
  • Moderate to severe valve disease
  • Recent (within 3 months) major CV event or planned procedures (within 6 months)
  • Terminal illness, life expectancy <6 months
  • Inability or unwillingness to comply with study requirements
  • No access to smart phone/tablet

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Publications

  • Ngo D, Sinha S, Shen D, Kuhn EW, Keyes MJ, Shi X, Benson MD, O'Sullivan JF, Keshishian H, Farrell LA, Fifer MA, Vasan RS, Sabatine MS, Larson MG, Carr SA, Wang TJ, Gerszten RE. Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease. Circulation. 2016 Jul 26;134(4):270-85. doi: 10.1161/CIRCULATIONAHA.116.021803. PMID 27444932
  • Jacob J, Ngo D, Finkel N, Pitts R, Gleim S, Benson MD, Keyes MJ, Farrell LA, Morgan T, Jennings LL, Gerszten RE. Application of Large-Scale Aptamer-Based Proteomic Profiling to Planned Myocardial Infarctions. Circulation. 2018 Mar 20;137(12):1270-1277. doi: 10.1161/CIRCULATIONAHA.117.029443. Epub 2017 Dec 8. PMID 29222138
  • Wallentin L, Eriksson N, Olszowka M, Grammer TB, Hagstrom E, Held C, Kleber ME, Koenig W, Marz W, Stewart RAH, White HD, Aberg M, Siegbahn A. Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. PLoS Med. 2021 Jan 13;18(1):e1003513. doi: 10.1371/journal.pmed.1003513. eCollection 2021 Jan. PMID 33439866
  • Sanders-van Wijk S, Tromp J, Beussink-Nelson L, Hage C, Svedlund S, Saraste A, Swat SA, Sanchez C, Njoroge J, Tan RS, Fermer ML, Gan LM, Lund LH, Lam CSP, Shah SJ. Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction: Results From the PROMIS-HFpEF Study. Circulation. 2020 Nov 24;142(21):2029-2044. doi: 10.1161/CIRCULATIONAHA.120.045810. Ep PMID 33034202
  • Santos-Parker JR, Santos-Parker KS, McQueen MB, Martens CR, Seals DR. Habitual aerobic exercise and circulating proteomic patterns in healthy adults: relation to indicators of healthspan. J Appl Physiol (1985). 2018 Nov 1;125(5):1646-1659. doi: 10.1152/japplphysiol.00458.2018. Epub 2018 Sep 20. PMID 30236049
  • Stattin K, Lind L, Elmstahl S, Wolk A, Lemming EW, Melhus H, Michaelsson K, Byberg L. Physical activity is associated with a large number of cardiovascular-specific proteins: Cross-sectional analyses in two independent cohorts. Eur J Prev Cardiol. 2019 Nov;26(17):1865-1873. doi: 10.1177/2047487319868033. Epub 2019 Aug 14. PMID 31409108
  • Contrepois K, Wu S, Moneghetti KJ, Hornburg D, Ahadi S, Tsai MS, Metwally AA, Wei E, Lee-McMullen B, Quijada JV, Chen S, Christle JW, Ellenberger M, Balliu B, Taylor S, Durrant MG, Knowles DA, Choudhry H, Ashland M, Bahmani A, Enslen B, Amsallem M, Kobayashi Y, Avina M, Perelman D, Schussler-Fiorenza Rose SM, Zhou W, Ashley EA, Montgomery SB, Chaib H, Haddad F, Snyder MP. Molecular Choreography of PMID 32470399
  • Robbins JM, Peterson B, Schranner D, Tahir UA, Rienmuller T, Deng S, Keyes MJ, Katz DH, Beltran PMJ, Barber JL, Baumgartner C, Carr SA, Ghosh S, Shen C, Jennings LL, Ross R, Sarzynski MA, Bouchard C, Gerszten RE. Human plasma proteomic profiles indicative of cardiorespiratory fitness. Nat Metab. 2021 Jun;3(6):786-797. doi: 10.1038/s42255-021-00400-z. Epub 2021 May 27. PMID 34045743

Identifiers

NCT: NCT06247774 · 2023p002781

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗